Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Pathology

How Do I Transfer Amyloidosis Slides for a Second Opinion?

At a Glance

For an amyloidosis second opinion, contact the receiving center before requesting materials. Follow its instructions for pathology slides or tissue blocks, original imaging, and complete records, and ask your care team what urgent treatment or monitoring should not wait while they are in transit.

When seeking a second opinion for amyloidosis, gathering your medical records, imaging, and biopsy materials can feel overwhelming. Standard patient portals are rarely enough to transfer everything a specialist needs to review a complex rare disease. Fortunately, the receiving center’s referral coordinator can often help you navigate this process.

Safety Note: Some forms of amyloidosis, particularly AL amyloidosis, can progress quickly. Ask your current medical team what treatments or monitoring cannot wait, and do not postpone urgent care solely because your records or slides are still in transit [1].

Step 1: Contact the Receiving Center First

Before requesting anything from your current hospital, contact the referral coordinator at your new amyloidosis center. Ask for their exact list of required materials, their preferred transfer methods, and their deadlines. Every center has different policies, and getting their instructions in writing will prevent you from requesting the wrong file formats or unnecessarily moving fragile tissue samples.

Step 2: Transferring Pathology Slides and Tissue Blocks

Identifying your exact amyloidosis subtype dictates your treatment. Advanced typing techniques, such as laser microdissection and mass spectrometry (a highly accurate method of identifying the exact protein causing the amyloidosis), often require physical tissue samples [2][3].

  • Ask What is Needed: The receiving pathology department will specify whether they need the original pathology report, Congo-red stained slides (used to visualize amyloid deposits), unstained slides, or the actual paraffin tissue block (the wax block containing your biopsy sample) [4].
  • Coordinate with Pathology: Call your current hospital to ask who handles pathology requests. While some hospitals route all requests through a central records office, the pathology department often handles loaned specimens directly.
  • Use Institutional Transfer: Because tissue blocks are a limited resource and inadequate tissue can prevent successful testing [4][5], many hospitals require an institution-to-institution transfer using an approved medical courier to maintain a chain of custody (a documented record of who held the specimen and where it was sent).
  • Do Not Mail Without Instructions: Do not repackage or mail slides yourself, and only hand-carry them if both hospitals provide explicit written authorization and instructions [6].

Step 3: Transferring Imaging Scans (Radiology)

Specialists rely heavily on imaging like echocardiograms, cardiac MRIs, and bone scintigraphy to evaluate organ involvement [7][8].

  • Request the Original Study: Patient portals sometimes only provide written reports or compressed images that lack necessary diagnostic detail. Ask the radiology department for the complete original diagnostic study in the format the receiving center accepts.
  • Understand DICOM: Often, centers will request DICOM files (the standard format for medical images that preserves high-resolution details and metadata) [9][10].
  • Digital vs. Physical Transfer: Ask if the receiving center uses a secure image-sharing link. If they require physical media (like a CD, DVD, or USB), handle it carefully. Some hospitals restrict outside CDs or flash drives due to cybersecurity risks like malware [11][12], so follow the receiving facility’s exact transfer protocol.

Step 4: Gathering Your Complete Medical Record

Under U.S. privacy laws (HIPAA), you have the right to access your designated record set and direct it to your new care team [13][14]. Ensure your request explicitly includes the following amyloidosis-specific records:

  • Original pathology reports and any addenda
  • Blood and urine tests, including serum and urine immunofixation and serum free light chains [1][15]
  • Organ function trends, such as kidney, liver, and heart markers [8]
  • Genetic testing results, which are vital for diagnosing hereditary ATTR amyloidosis [16]
  • Current medication lists and any prior treatments [17]

Common questions in this guide

What pathology materials might an amyloidosis specialist need for a second opinion?
An amyloidosis pathology team may request the original pathology report, slides stained to show amyloid deposits, unstained slides, or the paraffin block that contains the biopsy. Ask the receiving center for its exact list because protein typing may require physical tissue.
Can I mail or hand-carry my amyloidosis biopsy slides myself?
Do not package or mail biopsy slides or tissue blocks yourself unless both hospitals give explicit written instructions. In many cases, the sending institution ships them directly to the receiving pathology department through an approved medical courier to preserve a documented chain of custody.
What imaging files should I send for an amyloidosis second opinion?
Request the complete original imaging studies, not only written reports or low-detail portal copies. The receiving center may want DICOM files for echocardiograms, cardiac MRI, or bone scans and may require a secure upload link or approved physical media.
Which medical records are important for an amyloidosis second opinion?
Important records can include original pathology reports and addenda, blood and urine tests such as immunofixation and serum free light chains, kidney, liver, and heart function trends, genetic testing, medication lists, and prior treatments. Ask the receiving center for its exact requirements and the correct way to send them.
Should I wait for my second opinion before starting amyloidosis treatment?
Some forms of amyloidosis, especially AL amyloidosis, can worsen quickly. Ask your current care team which treatment or monitoring should begin before the second opinion, and do not delay urgent care just because records or tissue are still being transferred.
What happens if my original amyloidosis biopsy tissue is limited?
If the biopsy sample is limited, the receiving pathology team may need to prioritize which tests are most important because there may not be enough tissue for every analysis. Ask how the sample will be used and whether any remaining tissue will be returned to the original hospital.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific pathology materials do you need for my second opinion: the original report, stained slides, unstained slides, or the actual tissue block?
  2. 2.Should my current hospital send the pathology materials directly to your department, or is there an approved way for me to transport them myself?
  3. 3.Do you require my imaging scans on a physical CD, or does your facility have a secure upload link I can use for DICOM files?
  4. 4.Who is the best contact person in your office to confirm that all my physical records, scans, and slides have arrived before my consultation?
  5. 5.If my original biopsy tissue is limited, how will your pathology team prioritize which tests to run, and how will the remaining tissue be returned to my home hospital?

References

References (17)
  1. 1

    American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis.

    Kukreti V, Seftel M, Aguirre MA, et al.

    Blood advances 2026; (10(14)):5113-5152 doi:10.1182/bloodadvances.2025017073.

    PMID: 41592868
  2. 2

    A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue.

    Gilbertson JA, Theis JD, Vrana JA, et al.

    Journal of clinical pathology 2015; (68(4)):314-7 doi:10.1136/jclinpath-2014-202722.

    PMID: 25637636
  3. 3

    The sensitivity and specificity of the routine kidney biopsy immunofluorescence panel are inferior to diagnosing renal immunoglobulin-derived amyloidosis by mass spectrometry.

    Gonzalez Suarez ML, Zhang P, Nasr SH, et al.

    Kidney international 2019; (96(4)):1005-1009 doi:10.1016/j.kint.2019.05.027.

    PMID: 31447055
  4. 4

    Implementation and evaluation of amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometry.

    Mollee P, Boros S, Loo D, et al.

    Clinical proteomics 2016; (13()):30 doi:10.1186/s12014-016-9133-x.

    PMID: 27795698
  5. 5

    Toward Improving Practices for Submission of Diagnostic Tissue Blocks for National Cancer Institute Clinical Trials.

    Makhlouf H, Watson MA, Lankes HA, et al.

    American journal of clinical pathology 2020; (153(2)):149-155 doi:10.1093/ajcp/aqz141.

    PMID: 31613330
  6. 6

    Patients Who Take Home Their Surgical Pathology Specimens: A Preliminary Study.

    Gibson BA, Sobonya RE

    Academic pathology 2019; (6()):2374289519832502 doi:10.1177/2374289519832502.

    PMID: 30886892
  7. 7

    Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment.

    Zanwar S, Gertz MA, Muchtar E

    Journal of the National Comprehensive Cancer Network : JNCCN 2023; (21(1)):83-90 doi:10.6004/jnccn.2022.7077.

    PMID: 36630897
  8. 8

    Multimodal Imaging and Biomarkers in Cardiac Amyloidosis.

    Jung MH, Chang S, Han EJ, Youn JC

    Diagnostics (Basel, Switzerland) 2022; (12(3)) doi:10.3390/diagnostics12030627.

    PMID: 35328180
  9. 9

    Thirty Years of the DICOM Standard.

    Larobina M

    Tomography (Ann Arbor, Mich.) 2023; (9(5)):1829-1838 doi:10.3390/tomography9050145.

    PMID: 37888737
  10. 10

    Automatic classification of medical image modality and anatomical location using convolutional neural network.

    Chiang CH, Weng CL, Chiu HW

    PloS one 2021; (16(6)):e0253205 doi:10.1371/journal.pone.0253205.

    PMID: 34115822
  11. 11

    Cybersecurity Challenges for PACS and Medical Imaging.

    Eichelberg M, Kleber K, Kämmerer M

    Academic radiology 2020; (27(8)):1126-1139 doi:10.1016/j.acra.2020.03.026.

    PMID: 32418786
  12. 12

    Cybersecurity Protection for PACS and Medical Imaging: Deployment Considerations and Practical Problems.

    Eichelberg M, Kleber K, Kämmerer M

    Academic radiology 2021; (28(12)):1761-1774 doi:10.1016/j.acra.2020.09.001.

    PMID: 33023808
  13. 13

    Honoring Dental Patients' Privacy Rule Right of Access in the Context of Electronic Health Records.

    Ramoni RB, Asher SR, White JM, et al.

    Journal of dental education 2016; (80(6)):691-6.

    PMID: 27251351
  14. 14

    A Clinician's Guide to Privacy and Communication in the ICU.

    Francis L, Vorwaller MA, Aboumatar H, et al.

    Critical care medicine 2017; (45(3)):480-485 doi:10.1097/CCM.0000000000002190.

    PMID: 27922454
  15. 15

    Prevalence of Monoclonal Gammopathy in Wild-Type Transthyretin Amyloidosis.

    Geller HI, Singh A, Mirto TM, et al.

    Mayo Clinic proceedings 2017; (92(12)):1800-1805 doi:10.1016/j.mayocp.2017.09.016.

    PMID: 29202938
  16. 16

    Renal amyloidosis: a new time for a complete diagnosis.

    Feitosa VA, Neves PDMM, Jorge LB, et al.

    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica 2022; (55()):e12284 doi:10.1590/1414-431X2022e12284.

    PMID: 36197414
  17. 17

    Exploring patients' perceptions of accessing electronic health records: Innovation in healthcare.

    Wass S, Vimarlund V, Ros A

    Health informatics journal 2019; (25(1)):203-215 doi:10.1177/1460458217704258.

    PMID: 28457195

This page explains how to transfer amyloidosis biopsy materials, imaging, and medical records for informational purposes only and does not constitute medical advice. Ask your care team what treatment or monitoring should not wait while materials are being transferred.